Pay in 4 interest-free payments of $6.41 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Baseline Conditions: Consider baseline sleep quality, stress state, and physiological conditions which may influence DSIP responsiveness
See every Magnesium reference on this page Freshness: we automatically re-check this combination every week this pair was last checked August 2, 2026
Patients who might be considered for GLP-1 therapy (within licensed indications) and who may experience secondary benefits for binge eating behaviours include: Individuals with binge eating disorder and type 2 diabetes , where GLP-1 agonists address the primary diabetes indication whilst potentially helping with eating patterns Those with BED and obesity who meet NHS eligibility criteria for weight management medications (as defined by NICE TA875 for semaglutide or TA664 for liraglutide, which are narrower than the marketing authorisation) Patients who have not responded adequately to psychological interventions such as cognitive behavioural therapy (CBT) and who have concurrent metabolic conditions Those experiencing significant food cravings and loss-of-control eating as part of their weight management challenges However, important cautions and considerations apply
Due to their prolonged presence, the weight loss drugs are more potent and have a stronger effect on appetite suppression than the GLP-1 that is naturally produced in the body
(PubMed) Hatanaka Y, Higuchi T, Akiya Y, et al
The hope is that this plan helps take a load off your plate (haha no pun intended), and help you consistently eat enough to nourish your body, manage side effects, and hit your health and weight loss goals
